1. Home
  2. ELVN vs INVA Comparison

ELVN vs INVA Comparison

Compare ELVN & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELVN
  • INVA
  • Stock Information
  • Founded
  • ELVN 2016
  • INVA 1996
  • Country
  • ELVN United States
  • INVA United States
  • Employees
  • ELVN N/A
  • INVA N/A
  • Industry
  • ELVN Biotechnology: Pharmaceutical Preparations
  • INVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELVN Health Care
  • INVA Health Care
  • Exchange
  • ELVN Nasdaq
  • INVA Nasdaq
  • Market Cap
  • ELVN 1.1B
  • INVA 1.2B
  • IPO Year
  • ELVN 2020
  • INVA 2004
  • Fundamental
  • Price
  • ELVN $21.47
  • INVA $18.58
  • Analyst Decision
  • ELVN Strong Buy
  • INVA Buy
  • Analyst Count
  • ELVN 5
  • INVA 1
  • Target Price
  • ELVN $37.80
  • INVA N/A
  • AVG Volume (30 Days)
  • ELVN 248.6K
  • INVA 723.5K
  • Earning Date
  • ELVN 03-13-2025
  • INVA 02-27-2025
  • Dividend Yield
  • ELVN N/A
  • INVA N/A
  • EPS Growth
  • ELVN N/A
  • INVA 46.55
  • EPS
  • ELVN N/A
  • INVA 0.99
  • Revenue
  • ELVN N/A
  • INVA $352,745,000.00
  • Revenue This Year
  • ELVN N/A
  • INVA $16.20
  • Revenue Next Year
  • ELVN N/A
  • INVA N/A
  • P/E Ratio
  • ELVN N/A
  • INVA $18.73
  • Revenue Growth
  • ELVN N/A
  • INVA 21.46
  • 52 Week Low
  • ELVN $10.90
  • INVA $14.33
  • 52 Week High
  • ELVN $30.03
  • INVA $21.28
  • Technical
  • Relative Strength Index (RSI)
  • ELVN 42.14
  • INVA 63.73
  • Support Level
  • ELVN $20.16
  • INVA $17.01
  • Resistance Level
  • ELVN $23.08
  • INVA $17.53
  • Average True Range (ATR)
  • ELVN 1.60
  • INVA 0.28
  • MACD
  • ELVN -0.09
  • INVA 0.18
  • Stochastic Oscillator
  • ELVN 25.14
  • INVA 98.12

About ELVN Enliven Therapeutics Inc.

Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

About INVA Innoviva Inc.

Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.

Share on Social Networks: